Last reviewed · How we verify
Faricimab Injection [Vabysmo]
Faricimab Injection [Vabysmo] is a Small molecule drug developed by Junyeop Lee. It is currently FDA-approved. Also known as: Intravitreal injection.
Faricimab Injection [Vabysmo] is a marketed drug developed by Junyeop Lee, with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Faricimab Injection [Vabysmo] |
|---|---|
| Also known as | Intravitreal injection |
| Sponsor | Junyeop Lee |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Faricimab Injection [Vabysmo] CI brief — competitive landscape report
- Faricimab Injection [Vabysmo] updates RSS · CI watch RSS
- Junyeop Lee portfolio CI
Frequently asked questions about Faricimab Injection [Vabysmo]
What is Faricimab Injection [Vabysmo]?
Who makes Faricimab Injection [Vabysmo]?
Is Faricimab Injection [Vabysmo] also known as anything else?
What development phase is Faricimab Injection [Vabysmo] in?
Related
- Manufacturer: Junyeop Lee — full pipeline
- Also known as: Intravitreal injection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing